Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer
The DOI matches its Crossref record; 30 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose To correlate FDG activity on PET with the expression of glucose transporter proteins Glut-1 and Glut-3 in patients with early stage non-small cell lung cancer (NSCLC).Methods Over a 5 year period, all patients with a PET scan and clinical stage I NSCLC underwent an immunohistochemical analysis of their tumor for Glut-1 and Glut-3 expression. The amount of FDG uptake in the primary lesion was measured by a standardized uptake ratio (SUR) and correlated with immunohistochemical results.Results Seventy-three patients with a mean age of 66 years had clinical stage I disease. The final pathologic stage showed 64 patients with stage IA/B disease, eight with stage IIA disease, and one patient with pathologic stage IIIA (T1N2) disease. Glut-1 transporter expression was significantly higher than Glut-3 (P<0.0001), and although there was some association between the SUR and Glut-1 (P=0.085) and SUR and Glut-3 (P=0.074) expression, this did not reach statistical significance.Conclusions Glut-1 and Glut-3 transporter expression did not demonstrate a statistically significant correlation with FDG uptake in potentially resectable lung cancer. It appears that these transporters alone do not affect the variation in FDG activity in early stage NSCLC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prominent type of muscle glucose transporter is GLUT4, which is insulin-dependent [30,31,93], in contrast to tumors which mainly overexpress Glut-1 and Glut-3 transporters, which are not insulin-sensitive [27,29,94].”
Citations
Cites
Hamacher, K., Coenen, H. H., & Stöcklin, G. (1986) · PubMed · Cited by 1,351
(1992) · PubMed Central · doi:10.2967/jnumed.120.251744a · Cited by 1,172
Facilitative glucose transporters
MUECKLER, M. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18550.x · Cited by 1,093
Prospective investigation of positron emission tomography in lung nodules.
Lowe, V. J., Fletcher, J. W., Gobar, L., Lawson, M., Kirchner, P., Valk, P., Karis, J., Hubner, K., Delbeke, D., Heiberg, E. V., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1075 · Cited by 552
Self-citationFocal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
Patz, E. F., Lowe, V. J., Hoffman, J. M., Paine, S. S., Burrowes, P., Coleman, R. E., & Goodman, P. C. (1993) · Radiology · doi:10.1148/radiology.188.2.8327702 · Cited by 511
Self-citation(1995) · PubMed · Cited by 474
Wahl, R. L., Quint, L. E., Greenough, R. L., Meyer, C. R., White, R. I., & Orringer, M. B. (1994) · Radiology · doi:10.1148/radiology.191.2.8153308 · Cited by 430
Staging Non-Small Cell Lung Cancer with Whole-Body PET
Marom, E. M., McAdams, H. P., Erasmus, J. J., Goodman, P. C., Culhane, D. K., Coleman, R. E., Herndon, J. E., & Patz, E. F. (1999) · Radiology · doi:10.1148/radiology.212.3.r99se21803 · Cited by 384
Self-citationYounes, M., Brown, R. W., Stephenson, M., Gondo, M., & Cagle, P. T. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970915)80:6<1046::aid-cncr6>3.0.co;2-7 · Cited by 381
Bustamante, E., Morris, H. P., & Pedersen, P. L. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68900-3 · Cited by 314
Research works printed but not linked: 1
- Shelton, 1995, Diagnosis of bone metastasis in lung cancer by whole-body PET-PDG imaging: Comparison to conventional skeletal scintigraphy, J. Nucl. Med., 36, 200
Cited by
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Neumaier, B., Reske, S. N., & Hetzel, M. (2003) · PubMed · Cited by 439
Glucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
“As previously discussed, 2-18F-fluoro-2-deoxyglucose (18F-FDG) is a widely established clinical tool that is a substrate for GLUT-1 and GLUT-3 transporters [82], and 2NBDG, in which the C2 hydroxyl is replaced by nitrogen and a bulky aromatic system, is a widely used fluorescent glucose bioprobe which has been shown t…”
BackgroundUse of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007
MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., Danna, M., Inoue, T., Deniaud-Alexandre, E., Schipani, S., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.11.008 · Cited by 367
“blood flow [14], activity of glucose transporters [15] and hexokinase, and by glucose consumption [16].”
BackgroundJadvar, H., Alavi, A., & Gambhir, S. S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054098 · Cited by 227
“66) between tumor SUV and GLUT1 overexpression has been reported by other studies (40–42); however, this has not been observed by some investigators (43) or has been shown to also be the case with benign conditions (e.”
Backgroundvan Baardwijk, A., Dooms, C., van Suylen, R. J., Verbeken, E., Hochstenbag, M., Dehing-Oberije, C., Rupa, D., Pastorekova, S., Stroobants, S., Buell, U., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.027 · Cited by 196
Metadata
- Authors
- Marom, E. M., Aloia, T. A., Moore, M.-B., Hara, M., Herndon, J. E., Harpole, D. H., Goodman, P. C., & Patz, E. F.
- Affiliations
- Duke Medical Center (US)
- Nagoya City University (JP)
- Corresponding author
- Marom, Edith M
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 33
- Issue
- 2-3
- Pages
- 99-107
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2153804216
- Cited by
- 69
- References
- 35
- Citations by year
- 2023: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Lung Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- non-small cell lung cancer, early-stage lung cancer, FDG-PET, glucose transporter 1, GLUT3, FDG uptake, tumor glucose metabolism, immunohistochemistry, stage I non-small cell lung cancer
- MeSH terms
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunoenzyme Techniques, Lung, Lung Neoplasms, Male, Middle Aged, Monosaccharide Transport Proteins, Nerve Tissue Proteins, Tomography, Emission-Computed, Radiopharmaceuticals, Fluorodeoxyglucose F18, Glucose Transporter Type 1, Glucose Transporter Type 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. https://app.cochat.ai/papers/10.1016/s0169-5002(00)00250-6
- The paper
- Marom, E. M., Aloia, T. A., Moore, M.-B., Hara, M., Herndon, J. E., Harpole, D. H., Goodman, P. C., & Patz, E. F. (2001). Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. https://doi.org/10.1016/s0169-5002(00)00250-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.